Maintenance of GLUT4 expression in smooth muscle prevents hypertension‐induced changes in vascular reactivity
dc.contributor.author | Atkins, Kevin B. | en_US |
dc.contributor.author | Seki, Yoshinori | en_US |
dc.contributor.author | Saha, Jharna | en_US |
dc.contributor.author | Eichinger, Felix | en_US |
dc.contributor.author | Charron, Maureen J. | en_US |
dc.contributor.author | Brosius, Frank C. | en_US |
dc.date.accessioned | 2015-03-05T18:24:43Z | |
dc.date.available | 2016-04-01T15:21:07Z | en |
dc.date.issued | 2015-02 | en_US |
dc.identifier.citation | Atkins, Kevin B.; Seki, Yoshinori; Saha, Jharna; Eichinger, Felix; Charron, Maureen J.; Brosius, Frank C. (2015). "Maintenance of GLUT4 expression in smooth muscle prevents hypertension‐induced changes in vascular reactivity." Physiological Reports (2): n/a-n/a. | en_US |
dc.identifier.issn | 2051-817X | en_US |
dc.identifier.issn | 2051-817X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/110755 | |
dc.description.abstract | Previous studies have shown that expression of GLUT4 is decreased in arterial smooth muscle of hypertensive rats and mice and that total body overexpression of GLUT4 in mice prevents enhanced arterial reactivity in hypertension. To demonstrate that the effect of GLUT4 overexpression on vascular responses is dependent on vascular smooth muscle GLUT4 rather than on some systemic effect we developed and tested smooth‐muscle‐specific GLUT4 transgenic mice (SMG4). When made hypertensive with angiotensin II, both wild‐type and SMG4 mice exhibited similarly increased systolic blood pressure. Responsiveness to phenylephrine, serotonin, and prostaglandin F2α was significantly increased in endothelium‐intact aortic rings from hypertensive wild‐type mice but not in aortae of SMG4 mice. Inhibition of Rho‐kinase equally reduced serotonin‐stimulated contractility in aortae of hypertensive wild‐type and SMG4‐mice. In addition, acetylcholine‐stimulated relaxation was significantly decreased in aortic rings of hypertensive wild‐type mice, but not in rings of SMG4 mice. Inhibition of either prostacylin receptors or cyclooxygenase‐2 reduced relaxation in rings of hypertensive SMG4 mice. Inhibition of cyclooxygenase‐2 had no effect on relaxation in rings of hypertensive wild‐type mice. Cyclooxygenase‐2 protein expression was decreased in hypertensive wild‐type aortae but not in hypertensive SMG4 aortae compared to nonhypertensive controls. Our results demonstrate that smooth muscle expression of GLUT4 exerts a major effect on smooth muscle contractile responses and endothelium‐dependent vasorelaxation and that normal expression of GLUT4 in vascular smooth muscle is required for appropriate smooth muscle and endothelial responses.e12299In the smooth muscle of aortae of hypertensive mice, expression of GLUT4 is decreased. Maintenance of aortic smooth muscle GLUT4 expression prevents hypertension‐mediated changes in vasomotor response. These effects include decreasing/preventing endothelial dysfunction. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Contractility | en_US |
dc.subject.other | COX‐2 | en_US |
dc.subject.other | endothelial‐dysfunction | en_US |
dc.subject.other | GLUT4 | en_US |
dc.subject.other | IP‐receptors | en_US |
dc.subject.other | relaxation | en_US |
dc.title | Maintenance of GLUT4 expression in smooth muscle prevents hypertension‐induced changes in vascular reactivity | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Physiology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/110755/1/phy212299.pdf | |
dc.identifier.doi | 10.14814/phy2.12299 | en_US |
dc.identifier.source | Physiological Reports | en_US |
dc.identifier.citedreference | Marcus, R. G., R. England, K. Nguyen, M. J. Charron, J. P. Briggs, and F. C. 3rd Brosius. 1994. Altered renal expression of the insulin‐responsive glucose transporter GLUT4 in experimental diabetes mellitus. Am. J. Physiol. 267: F816 – F824. | en_US |
dc.identifier.citedreference | Banz, W. J., M. A. Abel, and M. B. Zemel. 1996. Insulin regulation of vascular smooth muscle glucose transport in insulin‐sensitive and resistant rats. Horm. Metab. Res. 28: 271 – 275. | en_US |
dc.identifier.citedreference | Bergandi, L., F. Silvagno, I. Russo, C. Riganti, G. Anfossi, E. Aldieri, et al. 2003. Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 23: 2215 – 2221. | en_US |
dc.identifier.citedreference | Brosius, F. C. 3rd, J. P. Briggs, R. G. Marcus, M. Barac‐Nieto, and M. J. Charron. 1992. Insulin‐responsive glucose transporter expression in renal microvessels and glomeruli. Kidney Int. 42: 1086 – 1092. | en_US |
dc.identifier.citedreference | Bryant, N. J., R. Govers, and D. E. James. 2002. Regulated transport of the glucose transporter GLUT4. Nat. Rev. Mol. Cell Biol. 3: 267 – 277. | en_US |
dc.identifier.citedreference | Cannon, C. P., and P. J. Cannon. 2012. COX‐2 inhibitors and cardiovascular risk. Science 336: 1386 – 1387. | en_US |
dc.identifier.citedreference | Feng, M., S. Whitesall, Y. Zhang, M. Beibel, L. D'Alecy, and K. DiPetrillo. 2008. Validation of volume‐pressure recording tail‐cuff blood pressure measurements. Am. J. Hypertens. 21: 1288 – 1291. | en_US |
dc.identifier.citedreference | Grassie, M. E., L. D. Moffat, M. P. Walsh, and J. A. MacDonald. 2011. The myosin phosphatase targeting protein (MYPT) family: a regulated mechanism for achieving substrate specificity of the catalytic subunit of protein phosphatase type 1 δ. Arch. Biochem. Biophys. 510: 147 – 159. | en_US |
dc.identifier.citedreference | Hilgers, R. H., J. Jr Todd, and R. C. Webb. 2007. Increased PDZ‐RhoGEF/RhoA/Rho kinase signaling in small mesenteric arteries of angiotensin II‐induced hypertensive rats. J. Hypertens. 25: 1687 – 1697. | en_US |
dc.identifier.citedreference | Hirano, K., D. N. Derkach, M. Hirano, J. Nishimura, and H. Kanaide. 2003. Protein kinase network in the regulation of phosphorylation and dephosphorylation of smooth muscle myosin light chain. Mol. Cell. Biochem. 248: 105 – 114. | en_US |
dc.identifier.citedreference | Hirano, K., M. Hirano, and H. Kanaide. 2004. Regulation of myosin phosphorylation and myofilament Ca2+ sensitivity in vascular smooth muscle. J. Smooth Muscle Res. 40: 219 – 236. | en_US |
dc.identifier.citedreference | Ito, M., T. Nakano, F. Erdodi, and D. J. Hartshorne. 2004. Myosin phosphatase: structure, regulation and function. Mol. Cell. Biochem. 259: 197 – 209. | en_US |
dc.identifier.citedreference | Katz, E. B., A. E. Stenbit, K. Hatton, R. DePinho, and M. J. Charron. 1995. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 377: 151 – 155. | en_US |
dc.identifier.citedreference | Lima, V. V., F. R. Giachini, H. Choi, F. S. Carneiro, Z. N. Carneiro, Z. B. Fortes, et al. 2009. Impaired vasodilator activity in deoxycorticosterone acetate‐salt hypertension is associated with increased protein O‐GlcNAcylation. Hypertension 53: 166 – 174. | en_US |
dc.identifier.citedreference | Lund‐Johansen, P. 1983. Haemodynamics in early essential hypertension–still an area of controversy. J. Hypertens. 1: 209 – 213. | en_US |
dc.identifier.citedreference | Marchesi, C., A. Rehman, Y. Rautureau, D. A. Kasal, M. Briet, A. Leibowitz, et al. 2013. Protective role of vascular smooth muscle cell PPAR? in angiotensin II‐induced vascular disease. Cardiovasc. Res. 97: 562 – 570. | en_US |
dc.identifier.citedreference | Mulvany, M. J. 2005. Abnormalities of the resistance vasculature in hypertension: correction by vasodilator therapy. Pharmacol. Rep. 57 ( Suppl. ): 144 – 150. | en_US |
dc.identifier.citedreference | Park, J. L., R. D. Loberg, D. Duquaine, H. Zhang, B. K. Deo, N. Ardanaz, et al. 2005. GLUT4 facilitative glucose transporter specifically and differentially contributes to agonist‐induced vascular reactivity in mouse aorta. Arterioscler. Thromb. Vasc. Biol. 25: 1596 – 1602. | en_US |
dc.identifier.citedreference | Seko, T., M. Ito, Y. Kureishi, R. Okamoto, N. Moriki, K. Onishi, et al. 2003. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ. Res. 92: 411 – 418. | en_US |
dc.identifier.citedreference | Tsao, T. S., R. Burcelin, E. B. Katz, L. Huang, and M. J. Charron. 1996. Enhanced insulin action due to targeted GLUT4 overexpression exclusively in muscle. Diabetes 45: 28 – 36. | en_US |
dc.identifier.citedreference | Virdis, A., A. Bacca, R. Colucci, E. Duranti, M. Fornai, G. Materazzi, et al. 2013. Endothelial dysfunction in small arteries of essential hypertensive patients: role of cyclooxygenase‐2 in oxidative stress generation. Hypertension 62: 337 – 344. | en_US |
dc.identifier.citedreference | Wang, J., W. Niu, Y. Nikiforov, S. Naito, S. Chernausek, D. Witte, et al. 1997. Targeted overexpression of IGF‐I evokes distinct patterns of organ remodeling in smooth muscle cell tissue beds of transgenic mice. J. Clin. Invest. 100: 1425 – 1439. | en_US |
dc.identifier.citedreference | Weber, D. S., and R. C. Webb. 2001. Enhanced relaxation to the rho‐kinase inhibitor Y‐27632 in mesenteric arteries from mineralocorticoid hypertensive rats. Pharmacology 63: 129 – 133. | en_US |
dc.identifier.citedreference | Wong, M. S., and P. M. Vanhoutte. 2010. COX‐mediated endothelium‐dependent contractions: from the past to recent discoveries. Acta Pharmacol. Sin. 31: 1095 – 1102. | en_US |
dc.identifier.citedreference | Wong, W. T., X. Y. Tian, and Y. Huang. 2013. Endothelial dysfunction in diabetes and hypertension: cross talk in RAS, BMP4, and ROS‐dependent COX‐2‐derived prostanoids. J. Cardiovasc. Pharmacol. 61: 204 – 214. | en_US |
dc.identifier.citedreference | Yu, Y., E. Ricciotti, R. Scalia, S. Y. Tang, G. Grant, Z. Yu, et al. 2012. FitzGerald. Vascular COX‐2 modulates blood pressure and thrombosis in mice. Sci. Transl. Med. 4: 132ra54. | en_US |
dc.identifier.citedreference | Armoni, M., C. Harel, M. Ramdas, and E. Karnieli. 2014. CYP2E1 Impairs GLUT4 gene expression and function: NRF2 as a possible mediator. Horm. Metab. Res. 46: 477 – 483. | en_US |
dc.identifier.citedreference | Atkins, K. B., D. Johns, S. Watts, R. Clinton Webb, and F. C. Brosius 3rd. 2001. Decreased vascular glucose transporter expression and glucose uptake in DOCA‐salt hypertension. J. Hypertens. 19: 1581 – 1587. | en_US |
dc.identifier.citedreference | Atkins, K. B., C. A. Northcott, S. W. Watts, and F. C. Brosius. 2005. Effects of PPAR‐gamma ligands on vascular smooth muscle marker expression in hypertensive and normal arteries. Am. J. Physiol. Heart Circ. Physiol. 288: H235 – H243. | en_US |
dc.identifier.citedreference | Atkins, K. B., A. Prezkop, J. L. Park, J. Saha, D. Duquaine, M. J. Charron, et al. 2007. Preserved expression of GLUT4 prevents enhanced agonist‐induced vascular reactivity and MYPT1 phosphorylation in hypertensive mouse aorta. Am. J. Physiol. Heart Circ. Physiol. 293: H402 – H408. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.